Primordial Genetics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Primordial Genetics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11317
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Primordial Genetics Inc (Primordial Genetics) is a biotechnology company that provides genetic and synthetic biology solutions for protein engineering and microbial improvement. The company develops improved bacterial and yeast strains for commercial protein production and protein expression. It uses function generator technology for genome-wide combination and re-assortment of coding sequences in translational fusions to generate novel genes. Primordial Genetics produces bacterial strains for creating L-methionine which is used in poultry and swine feed. The company also holds expertise in immunoglobulin expression in E.coli including monoclonal antibodies. It also assists in discovering proteins such as new therapeutics, enzymes, and trait genes for microbes and plants, among others. The company concentrates on the discovery and production of chemicals and pharmaceuticals through genetic optimizations of actinomycete bacteria and microbial sources of natural products. Primordial Genetics is headquartered in San Diego, California, the US.

Primordial Genetics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Primordial Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 9
Venture Financing 9
Primordial Genetics Raises USD0.4 Million in Venture Financing 9
Primordial Genetics Raises USD0.6 Million in Venture Financing 10
Primordial Genetics Raises Funds in Series A-2 Financing 11
Primordial Genetics Raises USD0.4 Million in Financing Round 12
Primordial Genetics Raises US$0.2 Million 13
Primordial Genetics Inc – Key Competitors 14
Primordial Genetics Inc – Key Employees 15
Primordial Genetics Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Government and Public Interest 17
Oct 01, 2018: Primordial Genetics awarded National Institutes of Health “America’s Seed Fund” grant 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Primordial Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
Primordial Genetics Raises USD0.4 Million in Venture Financing 9
Primordial Genetics Raises USD0.6 Million in Venture Financing 10
Primordial Genetics Raises Funds in Series A-2 Financing 11
Primordial Genetics Raises USD0.4 Million in Financing Round 12
Primordial Genetics Raises US$0.2 Million 13
Primordial Genetics Inc, Key Competitors 14
Primordial Genetics Inc, Key Employees 15

List of Figures
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Primordial Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[Primordial Genetics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Grupo Industrial Saltillo, S.A.B. de C.V.:企業の戦略・SWOT・財務情報
    Grupo Industrial Saltillo, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report Summary Grupo Industrial Saltillo, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • MILEI GmbH:戦略・SWOT・企業財務分析
    MILEI GmbH - Strategy, SWOT and Corporate Finance Report Summary MILEI GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • EVA Airways Corporation:戦略・SWOT・企業財務分析
    EVA Airways Corporation - Strategy, SWOT and Corporate Finance Report Summary EVA Airways Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ImmunoGen Inc (IMGN)-医療機器分野:企業M&A・提携分析
    Summary ImmunoGen Inc (ImmunoGen) is a biotechnology company that carries out the development of anticancer therapeutics. The company uses its proprietary antibody-drug conjugates (ADC) technology for the development of the products. It develops products for the treatment of various types of cancer …
  • Freehold Royalties Ltd (FRU):石油・ガス:M&Aディール及び事業提携情報
    Summary Freehold Royalties Ltd (Freehold Royalties), formerly Freehold Royalty Trust is an oil and gas company that offers oil and gas operation and financial performance. The company's oil and gas assets generate income from natural gas, crude oil, natural gas liquids and potash deposits. It provid …
  • Kobayashi Pharmaceutical Co Ltd (4967)-製薬・医療分野:企業M&A・提携分析
    Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body w …
  • Suzhou Xinrong Best Medical Instrument Co Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Suzhou Xinrong Best Medical Instrument Co Ltd (Suzhou Xinrong) is a medical device company that manufactures orthopedic medical instruments. The company offers products such as medullary cavity plug, acetabular screws, metal ball head, stem and titanium plate anterior thoracolumbar fixed equ …
  • Lake Shore Gold Corp.:企業のM&A・事業提携・投資動向
    Lake Shore Gold Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lake Shore Gold Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • CSE Global Ltd (544):石油・ガス:M&Aディール及び事業提携情報
    Summary CSE Global Limited (CSE) is a technology company offering process control systems and integrated plant communication systems. It’s process control systems offers emergency shutdown systems, process shutdown systems, integrated control & safety systems and fire and gas detection systems, well …
  • Fugro NV (FUR):企業の財務・戦略的SWOT分析
    Fugro NV (FUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Otsuka Pharmaceutical Co., Ltd.:企業のM&A・事業提携・投資動向
    Otsuka Pharmaceutical Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Otsuka Pharmaceutical Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • John Paul Mitchell Systems, Inc.:企業の戦略・SWOT・財務情報
    John Paul Mitchell Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary John Paul Mitchell Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Iksuda Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Iksuda Therapeutics Ltd (Iksuda), formerly Glythera Ltd is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based t …
  • Nuri Telecom Co., Ltd. (040160):企業の財務・戦略的SWOT分析
    Nuri Telecom Co., Ltd. (040160) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Service Corporation International (SCI):企業の財務・戦略的SWOT分析
    Service Corporation International (SCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • AIA Group Limited:戦略・SWOT・企業財務分析
    AIA Group Limited - Strategy, SWOT and Corporate Finance Report Summary AIA Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Selvita SA (SLV):企業の財務・戦略的SWOT分析
    Summary Selvita SA (Selvita) is a clinical stage biopharmaceutical company that develops small molecule therapies for the treatment of cancer. It is evaluating its pipeline candidates including SEL120, a selective CDK8 kinase inhibitor for the treatment of hematological malignancies and solid tumors …
  • The Mediterranean & Gulf Cooperative Insurance & Reinsurance Company (S.J.S.C):企業の戦略・SWOT・財務情報
    The Mediterranean & Gulf Cooperative Insurance & Reinsurance Company (S.J.S.C) - Strategy, SWOT and Corporate Finance Report Summary The Mediterranean & Gulf Cooperative Insurance & Reinsurance Company (S.J.S.C) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data …
  • Hays plc (HAS):企業の財務・戦略的SWOT分析
    Hays plc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Sir Robert McAlpine Ltd:企業の戦略的SWOT分析
    Sir Robert McAlpine Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆